MRK - Merck & Co., Inc.
| Previous close | 76.69 |
| Open | 76.75 |
| Bid | 76.84 x 1300 |
| Ask | 76.95 x 1000 |
| Day's range | 76.40 - 77.35 |
| 52-week range | 65.25 - 92.64 |
| Volume | 4,801,993 |
| Avg. volume | 10,550,028 |
| Market cap | 193.674B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 19.45 |
| EPS (TTM) | 3.94 |
| Earnings date | 31 Jul 2020 |
| Forward dividend & yield | 2.44 (3.18%) |
| Ex-dividend date | 12 Jun 2020 |
| 1y target est | 93.00 |
- Zacks
Merck's Keytruda Gets Priority Review for Lymphoma Indication
FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.
- Business Wire
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
- Yahoo Finance
Coronavirus update: Florida sees deadliest day yet as US cases spike, economy jitters grow
The U.S. saw yet another day of record coronavirus casualties on Thursday, led mostly by a relentless surge in the stricken Sun Belt region.
- Reuters
New $1 billion fund aims to steer antibiotic companies in tough market
Public health authorities have raised alarms about a looming health crisis, saying deaths from antibiotic-resistant bacteria could dwarf that from the COVID-19 pandemic. The fund, led by the International Federation of Pharmaceutical Manufacturers & Associations, seeks to serve as a temporary solution until new legislation can offer a more permanent fix in the market. It aims to help shore up investment in smaller biotech companies after several large drugmakers, such as Sanofi SA bowed out of the antibiotics space.
- Zacks
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.
- Business Wire
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Business Wire
Merck Announces Appointment of Organon & Co. General Counsel
Merck Announces Appointment of Organon & Co. General Counsel
- Yahoo Finance
Coronavirus update: US cases spike above 3M as WHO withdrawal draws more critics
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
- Business Wire
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
- Business Wire
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Merck and Eisai Receive Complete Response Letter for KEYTRUDA plus LENVIMA as First-Line Treatment for Unresectable Hepatocellular Carcinoma
- Reuters
AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer
The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo. Lynparza, which can now be used to treat patients with a form of BRCA-mutated metastatic pancreatic cancer, leads a class of drugs known as PARP inhibitors that stop cancer cells from repairing themselves after being damaged by chemotherapy.
- Zacks
Merck (MRK) Stock Moves -1.08%: What You Should Know
Merck (MRK) closed the most recent trading day at $78.72, moving -1.08% from the previous trading session.
- Business Wire
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Merck Announces New Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
- Stockopedia
Four clues to the quality of Merck amp; Co Inc (NYQ:MRK)
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that t...
- Simply Wall St.
How Many Merck & Co., Inc. (NYSE:MRK) Shares Do Institutions Own?
A look at the shareholders of Merck & Co., Inc. (NYSE:MRK) can tell us which group is most powerful. Institutions...
- Zacks
Why the Earnings Surprise Streak Could Continue for Merck (MRK)
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
- Business Wire
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
- Business Wire
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
- Zacks
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
- Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
- Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
FDA Approves Merck’s KEYTRUDA® for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC).
- Business Wire
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
- Zacks
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) closed the most recent trading day at $77.12, moving +0.48% from the previous trading session.
